Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease

Author:

Stanifer John W.1ORCID,Pokorney Sean D.23,Chertow Glenn M.4,Hohnloser Stefan H.5,Wojdyla Daniel M.3,Garonzik Samira6,Byon Wonkyung7,Hijazi Ziad8,Lopes Renato D.3,Alexander John H.23,Wallentin Lars8,Granger Christopher B.23

Affiliation:

1. Munson Nephrology, Munson Healthcare, Traverse City, MI (J.W.S.).

2. Division of Cardiology, Department of Medicine, Duke Health (S.D.P., J.H.A., C.B.G.), Duke University School of Medicine, Durham, NC.

3. Duke Clinical Research Institute (S.D.P., D.M.W., R.D.L., J.H.A., C.B.G.), Duke University School of Medicine, Durham, NC.

4. Division of Nephrology, Stanford University School of Medicine, CA (G.M.C.).

5. Johann Wolfgang Goethe University, Frankfurt, Germany (S.H.H.).

6. Clinical Pharmacology and Pharmacometrics, Bristol-Myers Squibb Company, Princeton, NJ (S.G.).

7. Global Product Development Clinical Pharmacology, Pfizer, Inc, Groton, CT (W.B.).

8. Department of Medical Sciences, Cardiology, and Uppsala Clinical Research Center (Z.H., L.W.), Uppsala University, Sweden.

Abstract

Background: Compared with the general population, patients with advanced chronic kidney disease have a >10-fold higher burden of atrial fibrillation. Limited data are available guiding the use of nonvitamin K antagonist oral anticoagulants in this population. Methods: We compared the safety of apixaban with warfarin in 269 patients with atrial fibrillation and advanced chronic kidney disease (defined as creatinine clearance [CrCl] 25 to 30 mL/min) enrolled in the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). Cox proportional models were used to estimate hazard ratios for major bleeding and major or clinically relevant nonmajor bleeding. We characterized the pharmacokinetic profile of apixaban by assessing differences in exposure using nonlinear mixed effects models. Results: Among patients with CrCl 25 to 30 mL/min, apixaban caused less major bleeding (hazard ratio, 0.34 [95% CI, 0.14–0.80]) and major or clinically relevant nonmajor bleeding (hazard ratio, 0.35 [95% CI, 0.17–0.72]) compared with warfarin. Patients with CrCl 25 to 30 mL/min randomized to apixaban demonstrated a trend toward lower rates of major bleeding when compared with those with CrCl >30 mL/min ( P interaction=0.08) and major or clinically relevant nonmajor bleeding ( P interaction=0.05). Median daily steady-state areas under the curve for apixaban 5 mg twice daily were 5512 ng/(mL·h) and 3406 ng/(mL·h) for patients with CrCl 25 to 30 mL/min or >30 mL/min, respectively. For apixaban 2.5 mg twice daily, the median exposure was 2780 ng/(mL·h) for patients with CrCl 25 to 30 mL/min. The area under the curve values for patients with CrCl 25 to 30 mL/min fell within the ranges demonstrated for patients with CrCl >30 mL/min. Conclusions: Among patients with atrial fibrillation and CrCl 25 to 30 mL/min, apixaban caused less bleeding than warfarin, with even greater reductions in bleeding than in patients with CrCl >30 mL/min. We observed substantial overlap in the range of exposure to apixaban 5 mg twice daily for patients with or without advanced chronic kidney disease, supporting conventional dosing in patients with CrCl 25 to 30 mL/min. Randomized, controlled studies evaluating the safety and efficacy of apixaban are urgently needed in patients with advanced chronic kidney disease, including those receiving dialysis. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00412984.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3